Compare AbbVie Inc (ABBV) vs Workday Inc (WDAY) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Workday (WDAY) trades at $179.64, up 5.52% over 24 hours, reflecting strong momentum. The stock shows bullish technical signals with moving averages supporting an uptrend, while RSI levels indicate potential overbought conditions. Fundamentally, the company has consistently beaten earnings expectations, with Q1 2026 EPS of $2.66 surpassing estimates of $2.51. Revenue growth is robust, projected to rise from $8.45B in 2025 to $9.9B in 2026, though net income margins have fluctuated. Recent news highlights partnerships and product launches, such as the Workday Adaptive Planning FedRAMP authorization announced on July 23, 2026.

The outlook for WDAY is positive, driven by earnings beats and strategic AI integrations, but elevated valuation ratios like a P/E of 55.96 pose risks. Investors should weigh growth potential against competitive pressures and market volatility, with analyst consensus leaning bullish but caution advised near technical resistance levels.